| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Maria Assunta Zocco | Q57070635 |
| P2093 | author name string | Antonio Gasbarrini | |
| Maurizio Pompili | |||
| Francesca D'Aversa | |||
| Francesca Romana Ponziani | |||
| P2860 | cites work | Mechanisms and therapeutic effectiveness of lactobacilli | Q27012999 |
| Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases | Q28131810 | ||
| Rifaximin treatment in hepatic encephalopathy | Q28277660 | ||
| The gut microbiota--masters of host development and physiology | Q28286102 | ||
| Beneficial effects of probiotic bifidobacterium and galacto-oligosaccharide in patients with ulcerative colitis: a randomized controlled study | Q83986587 | ||
| The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis | Q84290217 | ||
| Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome | Q84705462 | ||
| Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents | Q28300892 | ||
| Factors influencing the composition of the intestinal microbiota in early infancy | Q29614578 | ||
| The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing | Q29615054 | ||
| Gut Microbiota in Health and Disease | Q29616812 | ||
| Functional interactions between the gut microbiota and host metabolism | Q29616815 | ||
| Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation | Q29617796 | ||
| Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. | Q31142368 | ||
| A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. | Q33433931 | ||
| Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial | Q33440895 | ||
| Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study | Q33443147 | ||
| Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults | Q33450795 | ||
| Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome | Q33458234 | ||
| The microbiome in inflammatory bowel disease: current status and the future ahead | Q33664898 | ||
| The treatment-naive microbiome in new-onset Crohn's disease | Q33762817 | ||
| Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome | Q33861186 | ||
| Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis | Q33914907 | ||
| In vitro activity and fecal concentration of rifaximin after oral administration | Q33980321 | ||
| Bile acids improve the antimicrobial effect of rifaximin | Q34108534 | ||
| Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge | Q34143650 | ||
| Therapeutic role of rifaximin in inflammatory bowel disease: clinical implication of human pregnane X receptor activation | Q34214649 | ||
| Compositional and functional features of the gastrointestinal microbiome and their effects on human health | Q34274976 | ||
| Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome | Q34341766 | ||
| A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis | Q34369987 | ||
| In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species | Q34509301 | ||
| Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis | Q34525343 | ||
| Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential | Q34557101 | ||
| Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females | Q34574939 | ||
| The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers | Q34583322 | ||
| Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy | Q34658087 | ||
| Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks | Q34667649 | ||
| Molecular and phenotypic traits of in-vitro-selected mutants of Bifidobacterium resistant to rifaximin. | Q46607610 | ||
| Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates | Q47370646 | ||
| Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells | Q47945739 | ||
| Is generic rifaximin still a poorly absorbed antibiotic? A comparison of branded and generic formulations in healthy volunteers. | Q48003519 | ||
| Rifaximin is a gut-specific human pregnane X receptor activator | Q48605501 | ||
| Microbial butyrate and its role for barrier function in the gastrointestinal tract. | Q52887776 | ||
| Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. | Q53184076 | ||
| The effect of rifaximin on gut flora and Staphylococcus resistance. | Q54263702 | ||
| Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. | Q54288748 | ||
| Genetic and proteomic characterization of rifaximin resistance in Bifidobacterium infantis BI07 | Q56995385 | ||
| A Randomized Formula Controlled Trial of Bifidobacterium lactis and Streptococcus thermophilus for Prevention of Antibiotic-Associated Diarrhea in Infants | Q58227623 | ||
| Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles | Q59880418 | ||
| 'Blooming' in the gut: how dysbiosis might contribute to pathogen evolution | Q63968591 | ||
| Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin | Q68987866 | ||
| Decreased muscular radionuclide uptake in Tc-99m MIBI scintigraphy during paralytic phase of thyrotoxic periodic paralysis | Q80925813 | ||
| Oral probiotics reduce the incidence and severity of necrotizing enterocolitis in very low birth weight infants | Q81224806 | ||
| Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota | Q81402999 | ||
| Beneficial effects of long-term consumption of a probiotic combination of Lactobacillus casei Shirota and Bifidobacterium breve Yakult may persist after suspension of therapy in lactose-intolerant patients | Q83609570 | ||
| Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria | Q34722477 | ||
| Duodenal-mucosal bacteria associated with celiac disease in children. | Q34802876 | ||
| Rifaximin-mediated changes to the epithelial cell proteome: 2-D gel analysis | Q34901665 | ||
| Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome | Q35059823 | ||
| Role of the microbiome in energy regulation and metabolism | Q35100445 | ||
| Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection | Q35109773 | ||
| The HLA-DQ2 genotype selects for early intestinal microbiota composition in infants at high risk of developing coeliac disease. | Q35190089 | ||
| Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. | Q35233808 | ||
| Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis | Q35596222 | ||
| Understanding the Molecular Mechanisms of Rifaximin in the Treatment of Gastrointestinal Disorders--A Focus on the Modulation of Host Tissue Function | Q35706722 | ||
| Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach | Q35870133 | ||
| The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. | Q35973636 | ||
| Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation. | Q36009729 | ||
| Microbial degradation of complex carbohydrates in the gut | Q36295226 | ||
| Host-microbiota interactions in inflammatory bowel disease | Q36295242 | ||
| Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic | Q36404922 | ||
| Antibiotic-associated diarrhea accompanied by large-scale alterations in the composition of the fecal microbiota | Q36597847 | ||
| Bacterial overgrowth as a cause of irritable bowel syndrome | Q36629354 | ||
| Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut | Q37097658 | ||
| Consumption of fermented milk product with probiotic modulates brain activity | Q37340274 | ||
| The intestinal microbiota in inflammatory bowel diseases: time to connect with the host | Q37743105 | ||
| Long-term impacts of antibiotic exposure on the human intestinal microbiota | Q37779673 | ||
| Fermentation in the human large intestine: its physiologic consequences and the potential contribution of prebiotics | Q37944977 | ||
| VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study | Q39286213 | ||
| Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome | Q39348241 | ||
| Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells | Q39497021 | ||
| Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells | Q39659623 | ||
| Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei | Q39756592 | ||
| Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles | Q39783194 | ||
| Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora | Q43215557 | ||
| Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial | Q43363077 | ||
| Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial | Q43644098 | ||
| Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis | Q44319566 | ||
| Use of denaturing gradient gel electrophoresis for analysis of the stool microbiota of hospitalized patients | Q44462874 | ||
| Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. | Q45573898 | ||
| Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. | Q45826312 | ||
| A randomized, double-blind, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifidobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms | Q46116511 | ||
| Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis | Q46143449 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 4.0 International | Q34179348 |
| P433 | issue | 25 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | infection | Q166231 |
| rifamycin | Q388565 | ||
| human gut flora | Q739734 | ||
| bacteria | Q10876 | ||
| intestine | Q9639 | ||
| antibiotic | Q12187 | ||
| infectious disease | Q18123741 | ||
| P1104 | number of pages | 9 | |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 4491-4499 | |
| P577 | publication date | 2017-07-01 | |
| 2017-07-07 | |||
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation | |
| P478 | volume | 23 |
| Q94400760 | Antibiotic prophylaxis for people with cirrhosis and variceal bleeding |
| Q99929789 | Colonic diverticular disease |
| Q64105305 | Cyclic rifaximin therapy effectively prevents the recurrence of symptoms after exacerbation of symptomatic uncomplicated diverticular disease: a retrospective study |
| Q92795035 | Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma |
| Q91783628 | Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis |
| Q89668421 | Excellent response of severe aplastic anemia to treatment of gut inflammation: A case report and review of the literature |
| Q89533721 | Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction |
| Q89496342 | Insights into the role of intestinal microbiota in hematopoietic stem-cell transplantation |
| Q92032230 | Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives |
| Q97597582 | MICROBIOTA REPROGRAMMING FOR TREATMENT OF ALCOHOL-RELATED LIVER DISEASE |
| Q54965289 | Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. |
| Q55278061 | Managing portal hypertension in patients with liver cirrhosis. |
| Q90950687 | Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study |
| Q99414159 | New Insights into the Pathogenesis of Non-Alcoholic Fatty Liver Disease: Gut-Derived Lipopolysaccharides and Oxidative Stress |
| Q64067558 | Rifaximin Alters Intestinal Microbiota and Prevents Progression of Ankylosing Spondylitis in Mice |
| Q92980064 | Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study |
| Q91831427 | Role and Effective Therapeutic Target of Gut Microbiota in Heart Failure |
| Q64276819 | Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease |
| Q92149832 | The impact of gut microbiota manipulation with antibiotics on colon tumorigenesis in a murine model |
| Q90005300 | The role of intestinal microbiota in the pathogenesis of colorectal carcinoma |
| Q94543861 | Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered view |
Search more.